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Protocol
AbstrACt
Introduction The aim of the QUIDS study is to develop 
a decision support tool for the management of women 
with symptoms and signs of preterm labour, based on 
a validated prognostic model using quantitative fetal 
fibronectin (fFN) concentration, in combination with 
clinical risk factors.
Methods and analysis The study will evaluate 
the Rapid fFN 10Q System (Hologic, Marlborough, 
Massachusetts, USA) which quantifies fFN in a vaginal 
swab. In QUIDS part 2, we will perform a prospective 
cohort study in at least eight UK consultant-led 
maternity units, in women with symptoms of preterm 
labour at 22+0 to 34+6 weeks gestation to externally 
validate a prognostic model developed in QUIDS part 
1. The effects of quantitative fFN on anxiety will be 
assessed, and acceptability of the test and prognostic 
model will be evaluated in a subgroup of women and 
clinicians (n=30). The sample size is 1600 women (with 
estimated 96–192 events of preterm delivery within 
7 days of testing). Clinicians will be informed of the 
qualitative fFN result (positive/negative) but be blinded 
to quantitative fFN result. Research midwives will 
collect outcome data from the maternal and neonatal 
clinical records. The final validated prognostic model 
will be presented as a mobile or web-based application.
Ethics and dissemination The study is funded by 
the National Institute of Healthcare Research Health 
Technology Assessment (HTA 14/32/01). It has been 
approved by the West of Scotland Research Ethics 
Committee (16/WS/0068).
Version Protocol V.2, Date 1 November 2016.
trial registration number ISRCTN 
41598423andCPMS: 31277.
IntroduCtIon 
The overall aim of the QUIDS study is to 
develop a decision support tool for the 
management of women with symptoms and 
signs of preterm labour, based on a validated 
prognostic model using quantitative fetal 
fibronectin (fFN) testing. The study has been 
conceptually divided into two parts. In this, 
the protocol for QUIDS part 2, we detail 
the protocol for a prospective cohort study. 
This will externally validate a prognostic 
model developed in QUIDS part 1.1 More 
detailed background about the diagnosis of 
preterm labour and background to the study 
is provided in the introduction of QUIDS 
Protocol part 1.1 
fFN is a biochemical test of preterm labour 
which has the potential to help improve diag-
nosis of impending preterm delivery.2 Much 
of the evidence about fFN to date relates 
to the qualitative fFN test, which provides a 
positive or negative result on the basis of a 
single threshold of 50 ng/mL.2 3 This test has 
been largely replaced with the Rapid fFN 10Q 
System, which provides a concentration of 
fFN (quantitative fFN), and as a continuous 
variable, may be a more useful predictor of 
preterm delivery. fFN is now only available 
with a quantitative analyser in the UK, but 
there is no consensus as to which women to 
use the test in, or how to interpret the results.
The QUIDS study will address this evidence 
gap by providing evidence about the potential 
value of the quantitative fFN test, along with 
guidance about how to interpret results. Here, 
strengths and limitations of this study
 ► Validation of a prognostic model in a separate pro-
spective cohort study.
 ► Health economic analysis to determine cost-effec-
tiveness from National Health Service perspective.
 ► Not a randomised control trial to test effectiveness 
of the model on improved patient outcomes.
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we detail the protocol for external validation of a prognostic 
model developed in QUIDS part 1.1
MEthods And AnAlysIs
Aims and methodologies
The aim of the QUIDS study is to develop a decision support 
tool for the management of women with symptoms and signs 
of preterm labour, based on a validated prognostic model 
using quantitative fFN testing.
The study protocol has been divided into two parts (see 
flow chart figure 1). The protocols for parts 1 and 2 are 
reported in separate manuscripts.
In QUIDS Protocol part 1, we have described how 
we will perform (1) an individual participant data 
(IPD) meta-analysis and (2) and economic analysis. 
The protocol details how we will develop and internally 
validate a prognostic model using quantitative fFN (as 
a continuous variable) and other risk (prognostic) 
factors and to evaluate the added value of quantitative 
fFN towards this prognostic model performance. We 
will also provide an economic rationale for the prog-
nostic model and analyse its cost-effectiveness from the 
perspective of the National Health Service (NHS).
In this, the QUIDS Protocol part 2, we will detail 
the prospective cohort study to externally validate 
and, if necessary, refine the prognostic model. This 
will be performed in at least eight UK hospitals with 
different settings (rural/urban) and different levels of 
neonatal care facilities. In addition, acceptability 
of quantitative fFN testing, and effects on maternal 
anxiety will be performed. We will assess the potential 
cost-effectiveness of the final prognostic model/deci-
sion support tool. This additional analysis will allow 
us to model the full costs and effect impacts of the 
different prognostic model and compare these in a 
cost-effectiveness analysis to provide an evidence-based 
economic rationale for implementing the diagnostic 
tool in the NHS.
Figure 1 Flow chart illustrating the design of QUIDS study and conceptual division into part 1 and part 2. qfFN, quantitative 
fetal fibronectin. 
 o
n
 28 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020795 on 19 April 2018. Downloaded from 
3Stock SJ, et al. BMJ Open 2018;8:e020795. doi:10.1136/bmjopen-2017-020795
Open Access
Endpoints
The primary endpoint of the prognostic model is spon-
taneous preterm delivery within 7 days of qfFN test, 
in women less than 36 weeks’ gestation. This was influ-
enced by the preceding QUIDS Qualitative study, which 
included focus group consultation to determine the 
decisional needs of women, their partners and clinicians 
(online supplementary material). It is also a recognised 
clinically important endpoint, as antenatal steroids (which 
significantly reduce morbidity and mortality in preterm 
babies)4 are most effective if delivery occurs within 7 days 
of administration.
A secondary endpoint suggested by QUIDS Qualitative 
study (online supplementary material) consultation, was 
delivery within 48 hours of qfFN test. This analysis will be 
performed if feasible to do so within the constraints of 
the data available for model development and validation.1
health technologies being assessed
The trial will evaluate the Rapid fFN 10Q System (Hologic, 
Marlborough, Massachusetts, USA). This provides a 
concentration of fFN (ng/mL or INVALID) in a vaginal 
swab sample in 10 min. It is now the only commercially 
available fFN test system, and replaces the TLiQ rapid 
analyser system, which provided a qualitative fFN result 
(POSITIVE or NEGATIVE) based on a threshold of 
50 ng/mL. The Rapid fFN 10Q system is a point of care 
test, which clinical staff can easily perform. All reagents 
for fFN testing can be stored at room temperature and 
specimen collection kits, reagents, cassettes and the 10Q 
analyser can be kept in clinical areas where women with 
symptoms of preterm labour are assessed so they can be 
conveniently accessed.
Vaginal swab samples are analysed by lateral flow; solid-
phase immunochromatographic assay (the Rapid fFN 
Cassette) and interpreted in the 10Q Rapid analyser. 
Two hundred microlitres of the sample is pipetted into 
the sample application well of the Rapid fFN Cassette 
using a polypropylene or polyethylene pipette. The 
sample will then flow from an absorbent pad across a 
nitrocellulose membrane via capillary action through a 
reaction zone containing murine monoclonal anti-fFN 
antibody conjugated to blue microspheres (conjugate). 
The conjugate, embedded in the membrane, will be 
mobilised by the flow of the sample. The sample will 
then flow through a zone containing goat polyclonal anti-
human fibronectin antibody that captures the fibronec-
tin-conjugate complexes. The remaining sample will flow 
through a zone containing goat polyclonal antimouse 
IgG antibody that captures unbound conjugate, resulting 
in a control line. After 10 min of reaction time, the inten-
sities of the test line and control line are interpreted with 
the 10Q Rapid analyser and a printed result provided as 
a concentration in ng/mL (0≥500 ng/mL) or INVALID. 
The result is invalid if the test does not meet internal 
quality controls (QC) that are performed automatically 
with every test. In the event of an invalid result, the test 
can be repeated with any remaining clinical specimen. 
A QC can be performed by a reusable Rapid fFN 10Q 
QCette QC Device, which verifies that the analyser perfor-
mance is within specification.
target population
The target population is pregnant women attending 
hospital with signs and symptoms of preterm labour.
Validation and refinement of prognostic model
Population
The prospective cohort study will include women with 
signs and symptoms of preterm labour at 22+0 to 34+6 
weeks gestation in whom admission, transfer or treatment 
is being considered. These will be recruited from at least 
eight sites with a mix of rural/urban settings, and have 
different levels of neonatal care facilities, over 12 months.
Eligibility criteria
The following inclusion criteria will apply at screening 
assessment (all apply):
 ► Women who are 22+0 to 34+6 weeks (or earlier gesta-
tion if the fetus is considered potentially viable).
 ► Women showing signs and symptoms of preterm 
labour which may include any or all of back pain, 
abdominal cramping, abdominal pain, light vaginal 
bleeding, vaginal pressure, uterine tightenings or 
contractions.
 ► Women where hospital admission, interhospital 
transfer or treatment (antenatal steroids, tocolysis or 
magnesium sulfate) are being considered due to signs 
of preterm labour.
 ► Women aged 16 years or above.
The broad inclusion criteria reflect current clinical 
practice and enable the generalisability of the results of 
the trial for routine clinical care. We will include women 
who reattend 7 days or more after initial recruitment with 
signs and symptoms of preterm labour and also women 
who remain symptomatic but undelivered 7 days later 
in whom repeat testing by the clinician is deemed to 
be appropriate. This will be in line with manufacturer’s 
recommendation for fFN testing.
The following inclusion criteria will apply on speculum 
examination:
 ► Cervical dilation ≤3 cm.
 ► Intact membranes.
 ► No significant vaginal bleeding, as judged by the 
clinician.
 ► Once it has been established that the women meet 
the above criteria, on speculum examination, the fFN 
swab can be taken.
Participants who sign the consent but are not eligible 
on examination to have an fFN swab taken will still be 
enrolled and have outcome data collected.
The following exclusion criteria will apply:
 ► Contraindication to vaginal examination (eg, placenta 
praevia).
 ► Higher order multiple pregnancy (triplets or more).
 ► Moderate or severe vaginal bleeding.
 o
n
 28 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020795 on 19 April 2018. Downloaded from 
4 Stock SJ, et al. BMJ Open 2018;8:e020795. doi:10.1136/bmjopen-2017-020795
Open Access 
 ► Cervical dilatation greater than 3 cm.
 ► Confirmed rupture of membranes.
 ► Sexual intercourse, vaginal examination or trans-
vaginal ultrasound in the preceding 24 hours factors 
may invalidate results. These women will be initially 
excluded from the study, but can be included if still 
symptomatic after 24 hours, when fFN accuracy will be 
restored.
Co-enrolment
This trial involves validating a decision support tool 
relating to a test that is currently commonly used in clin-
ical practice. As such, there are no additional interven-
tions. Co-enrolment in other non-interventional trials 
will be allowed. Co-enrolment in trials of tocolytic treat-
ments or other management strategies that may influ-
ence timing of delivery as a primary outcome will not 
be allowed. Participation in QUIDs would not preclude 
babies being subsequently involved in interventional 
trials. Co-enrolment will be recorded in the electronic 
case report form (CRF).
Setting
The prospective cohort study will take place in at least 
eight consultant-led obstetric units in the UK. More than 
93% of pregnant women in the UK deliver in consul-
tant-led units.5 6 The vast majority of women with symp-
toms of preterm labour will present to a consultant-led 
unit for assessment, either directly or following advice 
from their community midwife or general practitioner.
The study will not include any community maternity units 
(staffed by midwives, with or without involvement of non-ob-
stetric medical staff), which cover a small proportion of 
women, mainly in remote and rural areas. In the Perinatal 
Collaborative Transport Study of perinatal transfers in Scot-
land,7 which involved 52 727 births, only 69 (0.13%) women 
were transferred to a consultant-led obstetric unit from 
community maternity units, and only a proportion of these 
were for suspected preterm labour. The small number of 
women cared for in community maternity units means their 
inclusion would not be an efficient use of study resources.
Given that management of women with symptoms of 
preterm labour and interhospital transfer patterns are 
likely to vary depending on level of available neonatal 
care and distance to transfer, we will include a mixture 
of hospitals with different levels of neonatal care facilities 
in both rural and urban settings. We will include units 
with special care units (providing special care for their 
own local population), local neonatal units (providing 
special care and high dependency care and a restricted 
volume of intensive care) and neonatal intensive care 
units (larger intensive care units providing the whole 
range of medical, and sometimes surgical neonatal care 
for their local population and for babies and their fami-
lies referred from the neonatal network in which they are 
based, and other networks when necessary). The hospi-
tals will be chosen from different geographical settings 
(rural/urban) and from different regions of the UK.
If additional units wish to participate in the study, we 
will consider including them, to increase recruitment 
rates. The UK Reproductive Health and Childbirth 
specialty group (clinical study group) have contributed 
to the study protocol and support the proposed trial.
Participant selection and enrolment
Women with signs and symptoms of preterm labour will 
be identified on presentation to obstetric services. A 
member of clinical staff, usually the doctor or midwife 
assessing the woman, will identify potentially eligible 
participants, provide a participant information leaflet 
and invite consent. A suitably trained member of clinical 
staff (doctor or midwife) or research team will consent 
participants.
Posters and leaflets will be situated in antenatal areas 
of participating hospitals to alert women that the study 
is taking place, and women will be allowed as much time 
as possible to consider participation without unduly 
delaying further clinical assessment. Participants will 
receive adequate oral and written information and appro-
priate participant information and informed consent 
forms will be provided.
Screening for eligibility
The clinical likelihood of preterm delivery is usually 
evaluated by history and examination, which includes 
abdominal palpation, to assess strength and frequency 
of uterine contractions. If preterm labour is suspected, 
a vaginal speculum examination is performed where the 
cervix is inspected for dilatation, and evidence of vaginal 
bleeding and membrane rupture assessed. Swabs for fFN 
are usually taken at this point. Potential participants in 
the QUIDS study will be identified after the initial assess-
ment and provided with information about the study. A 
combined ‘Screening and Consent Form’ will be used as 
a self-screening tool for potentially eligible participants. 
Informed consent will take place before speculum exam-
ination and the fFN swab has been taken. This approach 
means that samples are collected at routine speculum 
examination, as they would be if fFN is implemented in 
clinical practice, and participants avoid an additional 
vaginal examination.
Ineligible and non-recruited participants
Certain exclusion criteria can only be assessed at spec-
ulum examination (eg, vaginal bleeding or evidence of 
ruptured membranes), so a proportion of women will 
not be eligible for fFN testing after consent is given. 
These women will still be enrolled and delivery outcomes 
collected. The decision whether to use this data for anal-
ysis will be the decision of the chief investigator and 
statisticians.
Withdrawal of study participants
Women will be able to withdraw consent for us of their 
data at any time until the end of the study.
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Study assessments (see table 1)
Eligibility assessment (screening and recruitment)
Women presenting with signs and symptoms of preterm 
labour will be identified on presentation to obstetric 
services. The doctor or midwife assessing the woman will 
identify potentially eligible participants and provide an 
invitation letter and short information leaflet.
After the woman has had the opportunity to consider 
whether she would like to participate, she will be asked to 
complete the Screening and Consent Form. The clinician 
will then decide whether the fFN test can be carried out. 
If the test can be carried out (according to manufactur-
er’s guidelines), then the participant will be fully enrolled 
and that their delivery outcomes will still be collected.
If the woman declines to participate and she is willing to 
provide a reason for this, the reason given will be entered 
on to an anonymous log. Baseline demographics will be 
collected on consenting women, together with height 
and weight, information on medical history, obstetric 
history, estimated date of delivery and presenting signs 
and symptoms.
The original consent form will be stored in the Investi-
gator Site File, a copy is given to the woman, a copy added 
to the medical notes and a copy sent to the Trial Office.
After providing consent, the participant will be 
asked to complete a short State Trait Anxiety Inventory 
(STAI) questionnaire and complete a contact details 
form. They will also be issued with a letter thanking 
them for taking part in the trial and giving details of 
the second questionnaire to be completed.
Sample collection
Samples for analysis will be taken with an fFN spec-
imen collection kit, which consists of a sterile polyester 
tipped swab and a specimen transport tube containing 
1 mL extraction buffer (an aqueous solution 
containing protease inhibitors and protein preserva-
tives including aprotinin, bovine serum albumin and 
sodium azide). During speculum examination the 
sterile swab will be lightly rotated across the posterior 
fornix of the vagina for 10 s to absorb vaginal secre-
tions. Samples should be taken before any other swabs 
(eg, for microbiology) or cervical manipulation and 
the speculum lubricated with normal saline as other 
lubricants may interfere with the antibody-antigen 
reaction of the test. Following specimen collection 
the swab should be removed, immersed in extraction 
buffer, the shaft of the swab snapped off and the trans-
port tube sealed.
Before analysis, samples are gently mixed and as 
much liquid as possible expressed from the swab by 
rolling the tip against the inside of the tube.
Initial fFN test
The sample taken will be run at a near bedside Hologic 
Rapid fFN 10Q analyser, specially adapted for the 
QUIDS study. As fFN (or other similar biochemical 
tests of preterm labour) are part of standard care, it 
would be unethical to blind clinicians from the quali-
tative fFN result. The analyser will thus reveal a qual-
itative fFN result (positive/negative/invalid based on 
a 50 ng/mL threshold) for clinicians to base clinical 
decision-making on, according to local protocols. The 
quantitative fFN result, however, will be stored as a 
three-letter code, blinding caregivers from the result. 
Samples will be run as per manufacturers instructions 
(described above in the section ‘health technologies 
being assessed’).
Table 1 QUIDS study assessments
Visit
Attendance with signs and symptoms preterm labour
Screening and 
recruitment 24–48 hours 1–6 months Delivery
Inclusion/exclusion criteria ◉
Participant information sheet ◉
Consent form ◉
Demographics ◉
Obstetric history ◉
Symptoms and signs ◉
Quantitative fetal fibronectin (concentration 
ng/mL)
◉
Cervical length scan (if available) ◉
State Trait Anxiety Inventory Questionnaire ◉ ◉
Delivery details ◉
Neonatal outcomes ◉
Qualitative Acceptability Questionnaires 
(subgroup n=30)
◉
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Repeat fFN tests
If there is clinical indication for further fFN tests (eg, 
because of ongoing symptoms of preterm labour after 
7 days), the results will also be recorded.
Labour/delivery/neonatal assessments
Admission for delivery will not be a formal study visit, 
but data will be collected using information recorded in 
the participant’s notes. Delivery data will be collected on 
the maternal outcomes of delivery, including method of 
delivery, indication for delivery method, onset of labour, 
date and gestation of delivery and blood loss.
Questionnaires
All participants who are eligible to participate will be asked 
to complete a STAI questionnaire before the speculum 
examination. The same questionnaire will be repeated 
on 24–48 hours postexamination. The second question-
naire will be provided on paper with a prepaid envelope 
to be returned by post to the Trial Office. If not returned 
by post, the Trial Office may try to contact the participant 
(with the contact details provided), to complete the ques-
tionnaire over the phone.
Safety and quality assessments
The Hologic Rapid fFN 10Q analyser has integrated QC 
measures, and we will keep records of these as well as any 
additional staff training that occurs after the study starts. 
It is recommended that a daily precalibrated reusable QC 
cassette be inserted and analysed every 24 hours to verify 
that the analyser performance is within specification. A 
daily QC should be performed if one has not been done 
in the preceding 24 hours before a patient test is to be 
done. Logs of results are stored on the machine and can 
be downloaded, and we will also ask the participating 
sites to keep a monthly paper log of QC tests done. Each 
patient test has an internal QC, with a procedural control 
line that verifies the threshold level of signal by the instru-
ment. Sample flow detection ensures the sample travels 
across the cassette properly, and confirms absence of 
conjugate aggregation. We believe that these measures 
will help ensure the validity of results. However, to provide 
further evidence of integrity and comparability of results 
from each site, we will request that all participating sites 
enrol in the Wales External Quality Assurance Scheme 
(WEQAS) Point of Care Quality Assurance Scheme. 
WEQAS will provide a sample for analysis to each site 
bimonthly, and provide reports on analyser performance 
and variability.8
Data collection
Data for prognostic model validation and update of health 
economic model
We will collect data on all of the candidate predictors 
considered for inclusion in the prognostic model devel-
oped in the IPD meta-analysis (quantitative fFN concen-
tration, previous spontaneous preterm labour, gestation 
at fFN test, age, ethnicity, body mass index, smoking, 
deprivation index, number of uterine contractions in set 
time period, cervical dilatation, vaginal bleeding, previous 
cervical treatment for cervical intraepithelial neoplasia, 
cervical length (measured by transvaginal cervical length; 
when available), singleton/multiple pregnancy, tocolysis 
and fetal sex). Outcome data will include gestational age 
at delivery, date and time of delivery, administration of 
treatments for preterm labour (steroids, antibiotics, tocol-
ysis, magnesium sulfate) duration hospital admission, 
hospital transfer, onset of labour (preterm prelabour 
rupture of membranes, idiopathic preterm birth, medi-
cally indicated preterm birth (and indication)), place of 
delivery (base hospital, other hospital, outwith hospital), 
mode of delivery, neonatal admission, neonatal compli-
cations, perinatal mortality, congenital anomaly, sex and 
birth weight.
Screening data and data about quantitative fFN testing 
will be collected on paper-based CRFs and research 
midwives will input these into the web-based electronic 
database. Clinical outcome data will be collected from the 
medical records.
Maternal acceptability and anxiety
Maternal anxiety will be measured pretest and post-test 
(24–48 hours) using the validated STAI questionnaire. 
Acceptability of fFN testing and the decision support will 
be assessed using follow-up interviews (face to face or tele-
phone, according to maternal preference) which will be 
conducted with a subgroup of participants (n=30) purpo-
sively sampled and stratified according to geographical 
location, outcome (preterm labour or not) and anxiety 
scores. Acceptability will also be assessed in a cohort of 
clinicians (n=30).
Statistics and sample size calculation
Guidance for external validation suggests at least 10 events 
(preterm delivery within 7 days of test) are required for 
each covariate included in a prognostic model.9 10 Data 
from the cohorts included in our IPD meta-analysis 
suggest an event rate of between 6% and 12%.1 Based on 
these estimates a sample size of 1600 will provide 96 and 
192 events (preterm delivery within 7 days).
A UK study has shown that 8.9% of pregnant women 
present with symptoms of preterm labour and are eligible 
for quantitative fFN,11 and we anticipate 50% recruit-
ment rate is achievable, thus, overall 4.5% of maternities 
could be recruited. We will initially include eight units 
in the cohort study with a combined delivery rate of 
approximately 36 000 per annum. We anticipate that we 
will achieve target recruitment within 12 months (1 year 
x 36 000 x 0.089 x 0.5=1602). If, however, the recruit-
ment rate or event rate is lower than predicted, we will 
increase the number of sites included in the study and/
or the recruitment period, to ensure that a minimum 
of 60 events (preterm delivery within 7 days of test) are 
achieved, allowing for external validation of at least six 
covariates in our model.
It is possible that the IPD meta-analysis will find there 
is potential added value of combining quantitative fFN 
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testing with cervical length measurement.12 13 As cervical 
length measurement has significant resource require-
ment (estimated NHS cost £68.16 per test) and lack of 
out-of-hours provision further limits availability in many 
NHS hospitals, we think it is very unlikely that cervical 
length scanning will improve performance of the prog-
nostic model to such a degree as to make it cost-effective. 
We will assess the incremental costs and effects of cervical 
length measurement in the proposed health economic 
model performed in parallel with the IPD meta-analysis, 
and will feed into design considerations during the first 
iteration of the prognostic model.
If inclusion of cervical length ultrasound is found to 
be potentially cost-effective, we will assess the feasibility 
of including it in the prospective cohort study. We antic-
ipate that including cervical length measurement in the 
prospective cohort study would be extremely difficult 
in the current NHS setting as the majority of units do 
not have 24 hours availability of transvaginal ultrasound 
and/or trained personnel to perform scans. Inclusion of 
cervical length would also likely decrease recruitment rate 
(due to need for additional transvaginal ultrasound exam-
ination) and require significant additional resources.
Analysis
Validation of prognostic model
The prognostic model developed in the IPD will be 
externally validated using data collected in the prospec-
tive cohort data, using the measures of discrimination 
and calibration described in QUIDS Protocol part 1,1 
including R2, C statistic, calibration slope, calibration 
in the large and calibration plots of observed versus 
predicted risks across deciles (with Loess smoother). The 
average performance of the model will be summarised 
across the centres in the cohort study. Between-centre 
heterogeneity in performance will also be summarised, 
and reduced (if necessary) by recalibration techniques 
regarding the strategy for the choice of baseline risk 
(intercept). That is, the predictor effects will not be modi-
fied from the IPD meta-analysis model, but the intercept 
may need to be tailored to improve validation in UK 
centres (eg, for rural settings). Based on the findings, a 
final model and its implementation strategy will then be 
recommended for use.
Economic analysis
The economic model will be refined, integrated and 
updated with data from the prospective study cohort, 
so as the most up to date and validated evidence is used 
to inform a cost-effectiveness decision. Such an itera-
tive approach to economic evaluation is now well estab-
lished.14 15 The care pathway following diagnosis will be 
included in the economic analysis, using data from the 
cohort study such as the diagnostic test accuracy data, 
resource use data (ie, steroid use, other medications, time 
in hospital, hospital transfer) and secondary outcome 
data (ie, treatment of side effects, morbidity, mortality) 
so as to capture the full costs and effect impacts (quality 
of life, morbidity and mortality) for both the mother and 
baby. Resource use data will be combined with unit cost 
information from the British National Formulary16 and 
NHS reference costs.17 18 Outcomes will be reported as 
the incremental cost per correct diagnosis, and incre-
mental cost per quality-adjusted life year gained of the 
qfFN prognostic model compared with current practice 
(no qualitative fFN model). The analysis will adhere to the 
National Institute for Health and Care Excellence refer-
ence case and the recommended guidelines for decision 
modelling and reporting of economic analyses.18 Probabi-
listic sensitivity analysis will be undertaken to explore how 
uncertainty in the model inputs impact on the cost-effec-
tiveness outcome.19
Acceptability of fFN testing and effects on anxiety
Maternal anxiety will be measured before and after quan-
titative fFN testing using the validated STAI. The STAI 
Form Y is a widely used tool for measuring both tempo-
rary ‘state anxiety’ and the more general, long-standing 
‘trait anxiety’. The STAI is designed for the self-reported 
assessment of the intensity of feelings of apprehension, 
tension, nervousness and worry. STAI-Anxiety scores 
increase in response to physical danger and psychological 
stress, making it highly appropriate for this study. The use 
of STAI in pregnancy studies is discussed by Hundley et al 
and we will interpret the results accordingly.20
The questionnaire will be administered prior to fFN 
testing (baseline) and 24–48 hours after the test, to assess 
early reactions to the test and any acute anxiety prompted 
by the result of the test. We will also be able to assess any 
differences in those presented with a high-risk or low-risk 
result. Although it might be interesting to assess anxiety 
again in the latter stages of pregnancy, it is likely that, 
in this population, many pregnancies will not reach full 
term. Thus, we believe our strategy of repeat question-
naire administration will allow measurement of longer-
term anxiety induced or alleviated by the test, while 
minimising bias due to preterm or term delivery itself or 
loss to follow-up.
Follow-up interviews will be performed with a subgroup 
of participants (n=30) to enable deeper exploration of 
women’s views regarding fFN testing, to gain insight into 
the rationale for responses given in the questionnaires. 
Interviews will be conducted following confirmation of 
pregnancy status. Acceptability of the prognostic model 
will also be assessed with women and a group of clini-
cians. All interviews will be audio recorded with consent, 
and field notes taken to ensure an audit trail.
Decision support
We will develop a decision support tool in accordance 
with the guidelines produced by the International Patient 
Decision Aid Standards Collaboration.21 Scoping of deci-
sional requirements and how data should be presented 
was performed during focus group consultation as part 
of QUIDS Qualitative (online supplementary mate-
rial). A prototype decision support tool incorporating 
 o
n
 28 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020795 on 19 April 2018. Downloaded from 
8 Stock SJ, et al. BMJ Open 2018;8:e020795. doi:10.1136/bmjopen-2017-020795
Open Access 
the initial prognostic model, developed as part of the 
IPD meta-analysis, will be tested with women and clini-
cians, as part of the acceptability studies described above. 
A final version will be updated with the validated (and, 
if necessary revised) prognostic model generated from 
the prospective cohort study. The multidisciplinary trial 
steering committee (TSC) will oversee the development 
process, and decide how material is selected for inclusion.
trial management and oversight arrangements
Project management group
The trial will be coordinated by a project management 
group (PMG), consisting of the grant holders (chief inves-
tigator and coapplicants), the trial manager, representa-
tives from the Study Office and CHaRT (the supporting 
Clinical Trials Unit (CTU)), plus service user represen-
tatives (PAG). The PMG will meet approximately every 
4 months by teleconference or face to face.
The trial manager based in Edinburgh will oversee the 
study and will be accountable to the chief investigator. The 
trial manager supported by the trial administrator(s) will 
take responsibility for the day-to-day transaction of study 
activities. They will be supported by the CTU at CHaRT 
to provide expertise and guidance. The trial manager will 
be responsible for checking the CRFs for completeness, 
plausibility and consistency. Any queries will be resolved 
by the investigator or delegated member of the trial team.
A Delegation Log will be prepared for each site, 
detailing the responsibilities of each member of staff 
working on the trial.
TSC and data monitoring committee
A combined TSC and data monitoring committee (DMC) 
will oversee the conduct and progress of the trial. The 
terms of reference of the Committee will be developed 
separately. Members of the TSC/DMC will consist of 
experts and two patient representatives.
PAtIEnt And PublIC InVolVEMEnt
Patient representatives were consulted during the 
protocol development and have been invited to join the 
PMG and the TSC, and will thus be involved in the recruit-
ment to, and conduct of, the study. Coauthor SH-C is a 
patient representative. Prior to commencing QUIDS, we 
performed a qualitative study to determine the decisional 
needs of pregnant women with signs and symptoms of 
preterm labour, their partners and their caregivers. This 
is described in the separate protocol ‘QUIDS Qualita-
tive’ (online supplementary material). The end product 
of QUIDS will be a decision support aid to help clini-
cians, women and their partners decide on management 
of threatened preterm labour, based on the results of 
the quantitative fFN. In QUIDS Qualitative women and 
clinicians indicated that they would prefer this to be on 
web-based or mobile app-based format, presenting the 
risk of preterm birth within 7 days of testing. Social media 
will be used to signpost publications and conference 
presentations and highlight important findings. Twitter 
and Facebook will be used to disseminate findings to 
professional organisations, charities, stakeholders and 
the public. Communication to the general public will 
further be facilitated by our close links with charities such 
as Tommys.22
EthICs And dIssEMInAtIon
The study will be conducted in accordance with the prin-
ciples of Good Clinical Practice (GCP). Local research 
and development approvals will be obtained prior to 
commencement of the study at each site.
On completion of the study, the study data will be 
analysed and tabulated, and a clinical study report will 
be prepared in accordance with GCP guidelines. Results 
will be communicated to the academic community via 
the scientific literature, attendance at conferences and 
invited presentations. Summaries of results will also be 
made available to investigators for dissemination within 
clinics. We anticipate that the decision support will be 
made available as web-based application that will be made 
freely available, so clinicians can access it easily and it can 
be readily translatable into UK practice. If it is found to be 
effective in ruling out preterm delivery, it is likely that it 
will decrease unnecessary costly, and potentially harmful 
treatments in women who have symptoms suggestive of 
preterm labour but do not deliver early .
how patients are involved in this study
 Patient representatives were consulted during the 
protocol development and have been invited to join the 
PMG and the TSC. Prior to commencing QUIDS, we 
performed a qualitative study to determine the decisional 
needs of pregnant women with signs and symptoms of 
preterm labour, their partners and their caregivers. This 
is described in the separate protocol “QUIDS Qualitative” 
(online supplementary material). The end product of 
QUIDS will be a decision support aid to help clinicians, 
women and their partners decide on management of 
threatened preterm labour, based on the results of the 
quantitative fFN. In QUIDS Qualitative, women and 
clinicians indicated that they would prefer this to be on 
web-based or mobile app-based format, presenting the 
risk of preterm birth within 7 days of testing. 
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